BCART Biocartis Group NV

Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of major shareholdings)

Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of major shareholdings)



BIOCARTIS GROUP NV (Euronext Brussels: BCART)

PRESS RELEASE - REGULATED INFORMATION - 10 January 2024, 23:00 CET

Disclosure of transparency notification

(Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of major shareholdings)



1. Summary of notice

BIOCARTIS GROUP NV received a transparency notification on January 5, 2024, showing that JPMorgan Chase & Co., with registered office at c/o CT Corporation, 1209 Orange Street, Wilmington, DE19801, USA, following the acquisition of shares on January 3, 2024, exceeds the participation threshold of 5%.



2. Contents of the notification

The notification dated 5 January 2024 contains the following information:

  • Reason for the notification: Acquisition or disposal of voting securities or voting rights.
  • Notification by: a parent undertaking or a controlling person.
  • Person(s) required to notify : JPMorgan Chase & Co., with registered office at c/o CT Corporation, 1209 Orange Street, Wilmington, DE19801, USA.
  • Date on which the threshold is crossed: 03-01-2024
  • Threshold exceeded (in %): 5%
  • Denominator: 93,915,910
  • Notification details:



A) Voting rights attached to voting securities
Holders of voting rights







Previous noticeAfter the transaction
Number of voting rights



Number of voting rights% voting rights
Related to securitiesRegardless of the effectsRelated to securitiesRegardless of the effects
JPMorgen Chase & Co.0000%0%
JP Morgan Securities PLC04,837,10605.15%0%
JP Morgan Securities LLC05,00000.01%0%
TOTAL 4,842,10605.16%0%



B) Similar financial instrumentsAfter the transaction
Holders of equivalent financial instrumentsType of financial instrumentExpiration dateExercise period or date# voting rights that may be acquired if the instrument is exercised% of voting rightsSettlement
JP Morgan Securities PLCEquity SWAP 04/03/2024 – 04/02/202484,9270.09%cash
JP Morgan Securities LLCRight to take back lent shares  15,7120.02%physically
    100,6390.11% 
       
 TOTAL (A & B# voting rights% of voting rights 
    4,942,7455.26% 





























  • chain of controlled undertakings through which the holding is effectively held:



JPMorgan Chase & Co.

JPMorgan Chase Bank, National Association (100%)

JP Morgan International Finance Limited (100%)

JP Morgan Capital Holdings Limited (100%)

JP Morgan Securities plc (100%)

JPMorgan Chase & Co.

JPMorgan Chase Holdings LLC (100%)

JP Morgan Broker-Dealer Holdings Inc. (100%)

JP Morgan Securities LLC (100%)



3. Miscellaneous

This press release can be consulted on the website of BIOCARTIS GROUP NV via this link .

--- END ---



More information:

Investor Relations Biocartis Group NV

e-mail        

Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla™ trademark and logo are used trademarks owned by Biocartis. Please refer to the product labeling for applicable intended uses for each individual Biocartis product.

This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.

Forward-looking statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.





EN
10/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biocartis Group NV

 PRESS RELEASE

Press release Biocartis Group NV: Disclosure of transparency notificat...

Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings) BIOCARTIS GROUP NV (Euronext Brussels: BCART) PRESS RELEASE - REGULATED INFORMATION - 10 January 2024, 23:00 CET Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings) 1. Summary of notice BIOCARTIS GROUP NV received a transparency notification on January 5, 2024, of which an amended version was received on January 8, 2024, showing that...

 PRESS RELEASE

Press release Biocartis Group NV: Disclosure of transparency notificat...

Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of major shareholdings) BIOCARTIS GROUP NV (Euronext Brussels: BCART) PRESS RELEASE - REGULATED INFORMATION - 10 January 2024, 23:00 CET Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of major shareholdings) 1. Summary of notice BIOCARTIS GROUP NV received a transparency notification on January 5, 2024, showing that JPMorgan Chase & Co., with registered office a...

 PRESS RELEASE

Press release Biocartis Holdings Inc.: Recapitalization completed and ...

Press release Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion PRESS RELEASE - 22 November 2023, 10:00 CET BIOCARTIS HOLDINGS INC. RECAPITALIZATION COMPLETED AND PRODUCT PORTFOLIO EXPANSION The recapitalization of Biocartis was completed last week, strengthening the balance sheet with a new investment of €40 million and a €132 million conversion of debt to equity.Product portfolio expansion with the launch of three breast cancer products: the Idylla™ PIK3CA-AKT1 Mutation Assay and, in collaboration with our partner APIS, the APIS Breast Cancer Subtyping...

 PRESS RELEASE

Press release Biocartis NV: Biocartis Hosts Corporate Workshop and Ann...

Press release Biocartis NV: Biocartis Hosts Corporate Workshop and Announces Seven Idylla™ Abstracts to be Presented at AMP 2023 Annual Meeting PRESS RELEASE - 13 November 2023, 07:00 CET Biocartis Hosts Corporate Workshop and Announces Seven Idylla™ Abstracts to be Presented at AMP 2023 Annual Meeting Mechelen, Belgium and Itasca (IL), United States, 13 November 2023 – Biocartis, an innovative molecular diagnostics company, announces today that it will host a free corporate workshop at the Annual Meeting of the ‘Association for Molecular Pathology’ (AMP), a leading molecular diagnost...

 PRESS RELEASE

Press release Biocartis Group NV: Announcement regarding Enforcement b...

Press release Biocartis Group NV: Announcement regarding Enforcement by Secured Creditors PRESS RELEASE REGULATED INFORMATION 31 October 2023, 15:30 CET ANNOUNCEMENT REGARDING ENFORCEMENT BY SECURED CREDITORS The Company’s Secured Creditors have enforced their security over the shares of the Biocartis operating subsidiaries Enforcement not expected to impact Biocartis's customers, suppliers, partners or employees Mechelen, Belgium, 31 October 2023 – Biocartis Group NV (the “Company”) (Euronext Brussels: BCART) announces that it has been informed by its Secured Creditors (as defined below...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch